INDEPENDENT ASSESSMENT
Cerenome presents a substantially different verification case from a newly created private issuer. It is the renamed continuation of Nasdaq-listed Plus Therapeutics, Inc., not an unrelated startup and not a pooled investment fund. The SEC CIK 0001095981, Houston address, Delaware incorporation, public-company reporting history and management continuity all carry through the August 2026 name change. Its September 18, 2026 Form D therefore should be read alongside Cerenome's Forms 8-K and 10-Q rather than in isolation. The filing reports a $20 million Rule 506(b) offering, $3 million already sold to one investor and $17 million remaining. More importantly, Cerenome explained that the financing involves senior secured convertible notes with aggregate original principal of as much as $21,276,596 and a 6% original issue discount. That distinction explains why the contractual note principal is larger than the $20 million cash-financing figure shown on Form D; the two numbers are different measurements of the same financing structure rather than an obvious inconsistency.
THE REBRAND AND FINANCING CHAIN
The corporate-history trail is unusually clear. Cerenome was previously Plus Therapeutics, which itself followed Cytori Therapeutics and MacroPore. On August 3, 2026, Plus Therapeutics formally became Cerenome and changed its Nasdaq ticker from PSTV to CNSY while retaining CIK 0001095981 and SEC Exchange Act file number 001-34375. Only weeks later, the company entered into the new financing arrangement. The related securities purchase agreement dated September 4 authorized senior secured convertible notes with up to approximately $21.28 million of original principal, including an initial note tranche, a second tranche and additional notes. Cerenome subsequently described the financing publicly as a facility of up to $20 million with 3i, LP, with an initial funding tranche and additional capital tied to future conditions or milestones. The September 18 Form D reports the first sale on September 10 and one investor, which closely connects the private-placement notice to this publicly disclosed financing rather than to a separate unidentified fundraising program. The securities box on Form D covers debt, equity and rights to acquire another security, consistent with a convertible financing rather than a conventional equity-only private placement.
WEBSITE, BUSINESS AND ENTITY PENETRATION
The website penetration also supports the legal-entity match. Cerenome.com identifies the company as an integrated central nervous system oncology business combining precision diagnostics, targeted therapeutics and clinical data, while its investor-relations site carries the public-company disclosures and financing announcements under the same Cerenome identity. Its principal operating components include CNSide Diagnostics, LLC, a wholly owned subsidiary commercializing cerebrospinal-fluid testing for CNS cancers, and the REYOBIQ targeted radiotherapeutic program. During 2026 the company announced multiple commercial developments around CNSide, including payer arrangements and expansion of contracted coverage, CAP accreditation of its Houston clinical laboratory and a collaboration with Genomic Testing Cooperative to add next-generation sequencing capabilities. These operating details matter because they provide independently cross-checkable evidence beyond the Form D itself: the legal name, headquarters, executives, public ticker, SEC reporting entity, laboratory operation and product programs can all be followed through the company's broader disclosure history.
The strongest diligence issue is therefore not whether a traceable Cerenome entity exists; it is the company's financing dependence and execution risk. Cerenome's June 30, 2026 Form 10-Q reported approximately $2.37 million of cash and cash equivalents, approximately $6.22 million of investments, a $16.0 million net loss for the first six months of 2026 and approximately $13.4 million of net cash used in operating activities. The filing also reported an accumulated deficit of approximately $531.8 million and stated that these conditions raised substantial doubt about the company's ability to continue as a going concern. The later financing improves the liquidity picture relative to that June balance-sheet date, and management said the September facility extended its forecast cash runway into 2028, but investors should distinguish management's forward-looking runway estimate from the historical financial statements. Future access to the remaining financing tranches, commercialization of CNSide, clinical development costs, possible conversion of notes into equity and other capital-market transactions can materially change dilution and liquidity.
FINAL ASSESSMENT
Cerenome has a comparatively strong public verification trail: it is a Nasdaq-reporting company with a long-standing SEC CIK, an identifiable predecessor chain, current Exchange Act filings, a functioning corporate and investor-relations website, named executives and operating programs that can be matched across multiple disclosures. The September 2026 Form D is best understood as a financing notice connected to a senior secured convertible-note transaction, not as evidence that Cerenome is an SEC-approved investment product. The most important investor questions concern the economics of the convertible notes and original issue discount, conditions governing future tranches, potential dilution, repayment obligations, CNSide commercialization, REYOBIQ clinical execution and the liquidity risk disclosed in the company's latest quarterly filing. Cerenome's extensive SEC footprint makes identity verification relatively straightforward, but public-company status and a filed Form D do not eliminate biotechnology-development, financing or going-concern risk.
KEY FINDINGS
- Cerenome is the renamed Plus Therapeutics, not a newly formed unrelated company.
- CIK 0001095981 and the public-company SEC reporting chain remain continuous through the name change.
- The September 18, 2026 Form D reports a $20 million Rule 506(b) offering, with $3 million sold to one investor.
- The underlying notes can have up to approximately $21.28 million of original principal because the notes incorporate a 6% original issue discount.
- The Form D describes debt, equity and security-acquisition rights rather than pooled investment fund interests.
- Cerenome's website, Nasdaq ticker CNSY, Houston headquarters and SEC disclosures align with the Form D identity.
- CNSide Diagnostics and REYOBIQ provide operating-business evidence independent of the fundraising notice.
- The June 2026 10-Q disclosed significant losses, operating cash use and substantial doubt about continued operation as a going concern.
- Subsequent financing provides additional liquidity, but future tranches and business execution remain material diligence points.
SEC SNAPSHOT Former Name: Plus Therapeutics, Inc. Accession: 0001193125-26-395734 Film No.: 261391783 Filed: September 18, 2026 Exemption: Rule 506(b) Offering: $20,000,000 Sold: $3,000,000 Remaining: $17,000,000 Sales Commission: $0 Finder Fees: $0 Address: 6420 Levit Green Boulevard, Suite 310, Houston, TX 77021 Ticker: CNSY
PRIMARY EVIDENCE REVIEWED SEC Form D filed September 18, 2026 SEC Form 8-K covering the Cerenome name and ticker change SEC September 2026 financing disclosures and securities purchase agreement Cerenome Form 10-Q for the quarter ended June 30, 2026 Cerenome corporate website and investor-relations disclosures CNSide Diagnostics commercial, laboratory and payer announcements
IMPORTANT FORM D NOTICE A Form D is a notice filing used in connection with an exempt securities offering. Filing a Form D does not mean the SEC has approved Cerenome, approved the securities, verified the investment merits, guaranteed repayment or endorsed the company's business. Independent due diligence remains necessary.